Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Rafael Ríos-Tamayo, Agustín Martín-García, Carolina Alarcón-Payer, Dolores Sánchez-Rodríguez, Ana María del Valle Díaz de la Guardia, Carlos Gustavo García Collado, Alberto Jiménez Morales, Manuel Jurado Chacón & José Cabeza Barrera. (2017) Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy. Drug Design, Development and Therapy 11, pages 2399-2408.
Read now
Read now
Sara Grammatico, Laura Cesini & Maria Teresa Petrucci. (2016) Managing treatment-related peripheral neuropathy in patients with multiple myeloma. Blood and Lymphatic Cancer: Targets and Therapy 6, pages 37-47.
Read now
Read now
Leonardo Mirandola, Diane D. Nguyen, Rakhshanda L. Rahman, Fabio Grizzi, Yu Yuefei, José A. Figueroa, Marjorie R. Jenkins, Everardo Cobos & Maurizio Chiriva-Internati. (2014) Anti-Galectin-3 Therapy: A New Chance for Multiple Myeloma and Ovarian Cancer?. International Reviews of Immunology 33:5, pages 417-427.
Read now
Read now
Massimo Offidani, Laura Corvatta, Patrizia Caraffa, Pietro Leoni, Chiara Pautasso, Alessandra Larocca & Antonio Palumbo. (2014) Pomalidomide for the treatment of relapsed–refractory multiple myeloma: a review of biological and clinical data. Expert Review of Anticancer Therapy 14:5, pages 499-510.
Read now
Read now
Jacob P Laubach, Peter M Voorhees, Hani Hassoun, Andrzej Jakubowiak, Sagar Lonial & Paul G Richardson. (2014) Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Review of Hematology 7:1, pages 97-111.
Read now
Read now
Roberto Castelli, Nicola Orofino, Agnese Losurdo, Roberta Gualtierotti & Massimo Cugno. (2014) Choosing treatment options for patients with relapsed/refractory multiple myeloma. Expert Review of Anticancer Therapy 14:2, pages 199-215.
Read now
Read now
Eileen M Boyle, Guillemette Fouquet, Salomon Manier, Jordan Gauthier, Marie Pierre Noel, Claire Borie, Thierry Facon, Ismail Elalamy & Xavier Leleu. (2012) Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis. Expert Review of Hematology 5:6, pages 619-629.
Read now
Read now
Roberto Castelli, Antonino Cannavò, Fabio Conforti, Giovanni Grava & Agostino Cortelezzi. (2012) Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice. Immunopharmacology and Immunotoxicology 34:5, pages 740-753.
Read now
Read now
Jennifer G Gaultney, William K Redekop, Pieter Sonneveld & Carin A Uyl-de Groot. (2012) Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value. Expert Review of Anticancer Therapy 12:6, pages 839-854.
Read now
Read now
Articles from other publishers (18)
Chandru Gajendran, Subramanyam Janardhan Tantry, Naveen Sadhu M.Zainuddin Mohammed, Purushottam Dewang, Mahanandeesha Hallur, Sreekala Nair, Krishnakumar Vaithilingam, Basavaprabhu Nagayya, Sridharan Rajagopal & Dhanalakshmi Sivanandhan. (2023) Novel dual LSD1/HDAC6 inhibitor for the treatment of cancer. PLOS ONE 18:1, pages e0279063.
Crossref
Crossref
Sanyog Jain, Kaisar Raza, Ashish Kumar Agrawal & Ankur Vaidya. 2021. Nanotechnology Applications for Cancer Chemotherapy. Nanotechnology Applications for Cancer Chemotherapy
141
174
.
Hye‑Rim Won, Dong Hoon Lee, Soo‑Keun Yeon, Hyun‑Wook Ryu, Go Woon Kim & So Hee Kwon. (2019) HDAC6‑selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma. International Journal of Oncology.
Crossref
Crossref
Ota Fuchs. (2019) Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs. Cardiovascular & Hematological Disorders-Drug Targets 19:1, pages 51-78.
Crossref
Crossref
Laurent GarderetFrederique KuhnowskiBenoit BergeMurielle Roussel, Martine Escoffre-BarbeIngrid LafonThierry FaconXavier LeleuLionel KarlinAurore Perrot, Philippe MoreauGerald MaritAnne-Marie StoppaBruno RoyerCarine ChaleteixMourad TiabCarla AraujoPascal LenainMargaret MacroEric VoogLofti BenboubkerOlivier AllangbaEric JourdanFrederique Orsini-PiocelleSabine BrechignacJean-Richard EveillardKarim BelhadjMarc WetterwaldBrigitte PegourieArnaud JaccardJean-Claude EisenmannSylvie Glaisner, Mohamad MohtyCyrille HulinHerve Avet Loiseau, Claire MathiotMichel Attal. (2018) Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. Blood 132:24, pages 2555-2563.
Crossref
Crossref
Yousef Hijji, Ellis Benjamin, Jerry P. Jasinski & Ray J. Butcher. (2018)
Crystal structure of the thalidomide analog (3a
R
*,7a
S
*)-2-(2,6-dioxopiperidin-3-yl)hexahydro-1
H
-isoindole-1,3(2
H
)-dione
. Acta Crystallographica Section E Crystallographic Communications 74:11, pages 1595-1598.
Crossref
Crossref
Hans C. Lee, Tomer M. Mark & Jatin J. Shah. (2016) Practical Approaches to the Management of Dual Refractory Multiple Myeloma. Current Hematologic Malignancy Reports 11:2, pages 148-155.
Crossref
Crossref
Emily Rychak, Derek Mendy, Tao Shi, Yuhong Ning, Jim Leisten, Ling Lu, Karen Miller, Rama K. Narla, Robert Z. Orlowski, Heather K. Raymon, Chad C. Bjorklund, Anjan Thakurta, Anita K. Gandhi, Brian E. Cathers, Rajesh Chopra, Thomas O. Daniel & Antonia Lopez-Girona. (2016) Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma. British Journal of Haematology 172:6, pages 889-901.
Crossref
Crossref
Brian L. McClune & Sagar S. Patel. 2016. Plasma Cell Neoplasms. Plasma Cell Neoplasms
123
141
.
Joost Louis Marie Jongen, Annemiek Broijl & Pieter Sonneveld. (2014) Chemotherapy-induced peripheral neuropathies in hematological malignancies. Journal of Neuro-Oncology 121:2, pages 229-237.
Crossref
Crossref
Yao Jiang, Jiang Wang, Darlene M. Rozewski, Shamalatha Kolli, Chia-Hsien Wu, Ching-Shih Chen, Xiaoxia Yang, Craig C. Hofmeister, John C. Byrd, Amy J. Johnson & Mitch A. Phelps. (2014) Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue. Journal of Pharmaceutical and Biomedical Analysis 88, pages 262-268.
Crossref
Crossref
Alessandra LaroccaVittorio MontefuscoSara BringhenDavide RossiClaudia CrippaRoberto MinaMonica GalliMagda MarcattiGiacinto La VerdeNicola GiulianiValeria MagarottoTommasina GuglielmelliDelia Rota-ScalabriniPaola OmedéAlberto SantagostinoIleana Baldi, Angelo Michele Carella, Mario BoccadoroPaolo CorradiniAntonio Palumbo. (2013) Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood 122:16, pages 2799-2806.
Crossref
Crossref
Paul G. Richardson, Tomer M. Mark & Martha Q. Lacy. (2013) Pomalidomide: New immunomodulatory agent with potent antiproliferative effects. Critical Reviews in Oncology/Hematology 88, pages S36-S44.
Crossref
Crossref
Daniel Heintel, Alberto Rocci, Heinz Ludwig, Arnold Bolomsky, Simona Caltagirone, Martin Schreder, Sabine Pfeifer, Heinz Gisslinger, Niklas Zojer, Ulrich Jäger & Antonio Palumbo. (2013)
High expression of cereblon (
CRBN
) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
. British Journal of Haematology 161:5, pages 695-700.
Crossref
Crossref
Hans C. LeeJatin J. ShahRobert Z. Orlowski. (2013) Novel Approaches to Treatment of Double-Refractory Multiple Myeloma. American Society of Clinical Oncology Educational Book:33, pages e302-e306.
Crossref
Crossref
Roberto CastelliRoberta GualtierottiNicola OrofinoAgnese LosurdoSara GandolfiMassimo Cugno. (2013) Current and Emerging Treatment Options for Patients with Relapsed Myeloma. Clinical Medicine Insights: Oncology 7, pages CMO.S8014.
Crossref
Crossref
Alexander L. Ruchelman, Hon-Wah Man, Weihong Zhang, Roger Chen, Lori Capone, Jian Kang, Anastasia Parton, Laura Corral, Peter H. Schafer, Darius Babusis, Mehran F. Moghaddam, Yang Tang, Michael A. Shirley & George W. Muller. (2013) Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity. Bioorganic & Medicinal Chemistry Letters 23:1, pages 360-365.
Crossref
Crossref
A Lopez-Girona, D Mendy, T Ito, K Miller, A K Gandhi, J Kang, S Karasawa, G Carmel, P Jackson, M Abbasian, A Mahmoudi, B Cathers, E Rychak, S Gaidarova, R Chen, P H Schafer, H Handa, T O Daniel, J F Evans & R Chopra. (2012) Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26:11, pages 2326-2335.
Crossref
Crossref